Debt consolidation

CanSino’s COVID-19 vaccine candidate approved for military use in China – world

Press office (Reuters)

Beijing, China ●
Mon June 29, 2020

4:30 p.m.
China, CanSino, coronavirus, COVID-19, COVID-19 vaccines, military use, human trial, SARS-CoV-2, corona virus, novel coronavirus, pandemic
To free

The Chinese military has been given the green light to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it to be safe and has shown some efficacy, has the company announced on Monday.

Ad5-nCoV is one of eight Chinese vaccine candidates approved for human trials at home and abroad for respiratory disease caused by the novel coronavirus. The shot also gained approval for human testing in Canada.

China’s Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing. The vaccine candidate was jointly developed by CanSino and an Academy of Military Sciences (AMS) research institute.

“Ad5-nCoV is currently limited to military use only and its use cannot be extended to a wider vaccination range without the approval of the logistics support department,” CanSino said, referring to the department of Central military commission that approved the military use of the vaccine.

CanSino declined to disclose whether inoculation of the vaccine candidate is mandatory or optional, citing trade secrets, in an email to Reuters.

The military approval follows China’s decision earlier this month to offer two more vaccine candidates to employees of state-owned companies traveling abroad.

Phase 1 and 2 clinical trials of CanSino’s vaccine candidate have shown that it has the potential to prevent disease caused by the coronavirus, which has killed half a million people worldwide, but its commercial success cannot be guaranteed, the company said.

Separately, AMS received approval earlier this month to test its second investigational coronavirus vaccine in humans.

No vaccine has yet been approved for commercial use against the disease caused by the novel coronavirus, but more than a dozen vaccines from more than 100 candidates worldwide are being tested in humans.

Leave a Reply

Your email address will not be published. Required fields are marked *